All In Biotech

NDA 218784 · Servier

Voranigo

Vorasidenib · Oral · Isocitrate Dehydrogenase 1 Inhibitor; Isocitrate Dehydrogenase 2 Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Aug 6, 2024: To treat Grade 2 astrocytoma or oligodendroglioma

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Aug 6, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

22

5 Phase 3, 8 recruiting

FAERS reports

612

463 serious, 12 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 20, 2026.

VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) and Clinical Studies (14) ]. VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection. ( 1 )

Mechanism: Vorasidenib is a small molecule inhibitor that targets isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2) enzymes. In vitro, vorasidenib inhibited the IDH1 wild type and mutant variants, including R132H and the IDH2 wild type and mutant variants. In cell-based and in vivo tumor models expressing IDH1 or IDH2 mutated proteins, vorasidenib decreased production of 2-hydroxyglutarate (2-HG) and partially restored cellular differentiation.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 6, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
  • VORANIGO · VORASIDENIB 10MG · TABLET, ORAL · Prescription
  • VORANIGO · VORASIDENIB 40MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vorasidenib" as an intervention, any sponsor and status, largest first.

All 22 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • alanine aminotransferase increased83
  • aspartate aminotransferase increased68
  • fatigue67
  • malignant neoplasm progression46
  • seizure41
  • headache39
  • nausea38
  • hepatic cytolysis34
  • hepatic enzyme increased34
  • gamma-glutamyltransferase increased28
  • liver function test increased24
  • hepatotoxicity21

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20232
202442
2025313
2026255

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Voranigo (Vorasidenib Citrate)

2024 spending

$19.2M

Beneficiaries

201

495 claims

Per beneficiary

$95,729

$1,284.70 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$19,241,447

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7 on PubMed

Sponsor: Servier

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.